Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation

• DOI: 10.1038/s41408-024-01062-2
• Publication Date: 2024-05-17T07:02:53Z
• Authors: Oren Pasvolsky; Zhongya Wang; Denái R. Milton; Mark R. Tanner; Qaiser Bashir; Samer Srour; Neeraj Saini; Paul Lin; Jeremy Ramdial; Yago Nieto; Guilin Tang; Partow Kebriaei; Yosra Aljawai; Hina N. Khan; Hans C. Lee; Christine Ye; Krina K. Patel; Sheeba K. Thomas; Robert Z. Orlowski; Elizabeth J. Shpall; Richard E. Champlin; Muzaffar H. Qazil...
• Keywords: Hematology; Autologous stem-cell transplantation

Autologous stem cell transplantation (autoHCT) is considered standard of care for newly diagnosed multiple myeloma (MM). Although most patients eventually progress after autoHCT, a small proportion achieve durable response. In this retrospective study we included 1576 patients, 244 (15%) whom were long-term responders (LTR), defined as having progression-free survival (PFS) ≥8 years transplant. Patients in the LTR group younger than non-LTR (median age 58.4 vs. 59.5 years; p = 0.012), less likely to have high-risk cytogenetics (4% 14%; < 0.001), more often had <50% bone marrow plasma cells (67% 58%; 0.018) and R-ISS stage I disease (43% 34%). More received post-transplant maintenance (63% 52%; 0.002). higher rates complete response (CR) at day100 (41% 27%; 0.001) best (70% 37%; compared group. groups median PFS 169.3 months overall (OS) not been reached. The leading cause death was progression. conclusion, 15% cohort upfront with distinct characteristics 14 years.